Brexit Bulletin: marketing authorisations for centrally-authorised medicinal products post Brexit
26 June 2017
Industries: Life Sciences and Healthcare
On 31 May 2017, the European Commission and the European Medicines Agency (EMA) published a list of Q&A “related to the United Kingdom’s withdrawal from the European Union with regard to the medicinal products for human and veterinary use within the framework of the Centralised Procedure” (“the Q&A document”).
Read the full article